<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547794</url>
  </required_header>
  <id_info>
    <org_study_id>CRD 310</org_study_id>
    <nct_id>NCT00547794</nct_id>
  </id_info>
  <brief_title>AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF</brief_title>
  <acronym>AVERT-AF</acronym>
  <official_title>AVERT-AF: Atrio-VEntricular Junction Ablation Followed by Resynchronization Therapy in Patients With Congestive Heart Failure and Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the combination of AVJ ablation followed by BiV&#xD;
      pacing significantly improves functional status and exercise capacity compared to&#xD;
      pharmacologic rate control in patients with chronic AF and depressed ejection fraction,&#xD;
      regardless of rate or QRS duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a prospective, randomized, double blinded, multicenter study&#xD;
&#xD;
        -  Patients meeting all the enrollment criteria are screened at enrollment and randomized&#xD;
           to Group 1 (Pharmacological therapy + Single Chamber ICD) or Group 2 (AVJ Ablation +&#xD;
           CRT-D)&#xD;
&#xD;
        -  Screened patients are implanted with a FDA approved SJM ICD/CRT-D with compatible lead&#xD;
           system&#xD;
&#xD;
        -  Patients are followed at 1, 3, 6 and 12 months post implant&#xD;
&#xD;
        -  Total # of centers - 20 centers&#xD;
&#xD;
        -  Sample size - 180 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in patient enrollment&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise duration</measure>
    <time_frame>12 month post implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) via Minnesota Living With Heart Failure (MLWH) questionnaire</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Class Progression</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>12 month post implant</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT-D + AVJ Ablation</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-Chamber ICD + Pharmacological Therapy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with history of permanent AF and CHF&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic permanent AF&#xD;
&#xD;
          -  Class I or II indication for ICD&#xD;
&#xD;
          -  LVEF ≤ 35% within 6 months&#xD;
&#xD;
          -  NYHA class II or III with a history of CHF&#xD;
&#xD;
          -  Maximal tolerated drug therapy for CHF and rate control with a stable regimen for ≥ 30&#xD;
             days&#xD;
&#xD;
          -  Ability to independently comprehend and complete a QoL questionnaire&#xD;
&#xD;
          -  Ability to give informed consent for study participation and willingness and ability&#xD;
             to comply with prescribed follow-up tests and scheduled evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paroxysmal or persistent AF&#xD;
&#xD;
          -  Class I indication for pacing (including AVJ ablation for poor rate control)&#xD;
&#xD;
          -  Ability to walk ≥ 450 meters in 6 minutes&#xD;
&#xD;
          -  Musculoskeletal disorders that prohibit the completion of a 450 meters walk&#xD;
&#xD;
          -  NYHA class I or IV at the time of enrollment&#xD;
&#xD;
          -  A contraindication to taking Coumadin therapy&#xD;
&#xD;
          -  History of myocardial infarction, percutanous coronary intervention, or CABG in the&#xD;
             past 30 days&#xD;
&#xD;
          -  History of mitral valve surgery&#xD;
&#xD;
          -  Prior attempts for cardiac resynchronization therapy&#xD;
&#xD;
          -  The presence of an existing coronary sinus lead or epicardial lead&#xD;
&#xD;
          -  Life expectancy &lt; 1year&#xD;
&#xD;
          -  Age &lt; 18 yrs&#xD;
&#xD;
          -  Current participation in other clinical studies except registry trials&#xD;
&#xD;
          -  Use of calcium channel blockers&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hamdan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hamdan MH, Freedman RA, Gilbert EM, Dimarco JP, Ellenbogen KA, Page RL. Atrioventricular junction ablation followed by resynchronization therapy in patients with congestive heart failure and atrial fibrillation (AVERT-AF) study design. Pacing Clin Electrophysiol. 2006 Oct;29(10):1081-8.</citation>
    <PMID>17038140</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

